Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Gross Profit (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Gross Profit for 16 consecutive years, with $12.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Gross Profit fell 5.83% to $12.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $49.7 million, a 12.84% decrease, with the full-year FY2024 number at $54.8 million, down 17.11% from a year prior.
  • Gross Profit was $12.0 million for Q3 2025 at Harvard Bioscience, up from $11.5 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $19.6 million in Q4 2021 to a low of $11.5 million in Q2 2025.
  • A 5-year average of $15.0 million and a median of $15.4 million in 2021 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: fell 25.36% in 2022, then increased 20.99% in 2023.
  • Harvard Bioscience's Gross Profit stood at $19.6 million in 2021, then fell by 19.05% to $15.8 million in 2022, then rose by 3.11% to $16.3 million in 2023, then decreased by 14.17% to $14.0 million in 2024, then dropped by 14.2% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Gross Profit are $12.0 million (Q3 2025), $11.5 million (Q2 2025), and $12.2 million (Q1 2025).